the food and drug administration authorized eli lilly‘s covid19 antibody cocktail for use as a prophylaxis in people who have been exposed to the virus giving a boost to the beleaguered shares of one of lilly’s partners on the drug abcellera biologics abcellera ticker abcl collaborated with lilly lly on the development of balmanivimab one of the two antibodies in the cocktail authorized by the fda late on thursday shares of abcellera which are down 508 this year as of the close of trading on thursday were up